UHRF1 and cerebral cavernous malformation: We hypothesize that the anticancer effects including reduced viability, apoptosis induction, and cell cycle arrest accompanying the treatment with NaBu and the combination treatment of CCM and NaBu, can be, at least in part, related to UHRF1 downregulation.